TradeFlare's AI research teams analysed ABSI on 18 market nights between May 11, 2026 and October 8, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 8, 2026 | HOLD | $9.22 | — / — | not yet | not yet | The current market regime and the stock's technical and fundamental profile do not support a conviction BUY. |
| September 25, 2026 | HOLD | $10.35 | — / — | +13.7% | not yet | The current market regime and stock-specific factors do not support a BUY recommendation at this time. |
| September 24, 2026 | HOLD | $9.74 | — / — | +3.9% | not yet | The stock is in a neutral market regime and the technicals are mixed, making it unsuitable for a buy at this time. |
| September 23, 2026 | HOLD | $10.71 | — / — | +10.5% | not yet | The current setup does not warrant a buy, and the stock is in a neutral market environment. |
| September 22, 2026 | HOLD | $9.82 | — / — | -5.3% | not yet | The stock is currently in a holding pattern due to conflicting signals and risk factors. |
| July 24, 2026 | BUY | $8.07 | — / — | +2.9% | +26.3% | Positive news sentiment driven by strong Phase 1 data for its hair loss drug. |
| July 23, 2026 | BUY | $8.24 | — / — | -5.3% | +15.0% | The current market regime and stock-specific factors do not support a new entry at this time. |
| July 22, 2026 | BUY | $8.32 | — / — | -16.3% | +21.2% | Positive Phase 1 clinical trial data for ABS-201. |
| July 21, 2026 | HOLD | $8.16 | — / — | -14.3% | +6.4% | The current market regime and the stock's technical and fundamental profiles do not support a new entry. |
| July 20, 2026 | HOLD | $8.30 | — / — | -7.3% | +13.2% | The scanner triggered a mean-reversion signal, but the overall technical and fundamental picture is bearish. |
| July 17, 2026 | BUY | $8.23 | — / — | -8.9% | +10.7% | Positive Phase 1 clinical trial data for ABS-201. |
| July 16, 2026 | BUY | $9.76 | — / — | -1.9% | +14.9% | Positive news flow driven by encouraging clinical trial results for ABS-201. |
| July 13, 2026 | BUY | $10.60 | — / — | -20.1% | -11.8% | Positive Phase 1 trial results for ABS-201 program. |
| July 8, 2026 | BUY | $11.33 | — / — | -12.1% | -24.3% | Insider buying from a director, indicating potential confidence in the company's future. |
| July 2, 2026 | BUY | $11.11 | $12.50 / $8.50 | -8.8% | -33.0% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| July 1, 2026 | BUY | $11.59 | $14.48 / $9.85 | +3.2% | -31.2% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| June 5, 2026 | HOLD | $7.34 | — / — | +6.2% | +77.0% | Potential for continued momentum on the 52-week breakout. |
| May 11, 2026 | BUY | $5.90 | — / — | -14.4% | +18.2% | Continued positive progress in ABS-201 trials. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.